Gotowa bibliografia na temat „Drugs design”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Drugs design”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Drugs design"
Bugg, Charles E., William M. Carson i John A. Montgomery. "Drugs by Design". Scientific American 269, nr 6 (grudzień 1993): 92–98. http://dx.doi.org/10.1038/scientificamerican1293-92.
Pełny tekst źródłaBORMAN, STU. "DRUGS BY DESIGN". Chemical & Engineering News Archive 83, nr 48 (28.11.2005): 28–30. http://dx.doi.org/10.1021/cen-v083n048.p028.
Pełny tekst źródłaKrasnopolsky, Yu М. ""QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION". Biotechnologia Acta 13, nr 6 (grudzień 2020): 5–12. http://dx.doi.org/10.15407/biotech13.06.005.
Pełny tekst źródłaSnyder, Solomon H. "Pharmacology: Virtuoso design of drugs". Nature 323, nr 6086 (wrzesień 1986): 292–93. http://dx.doi.org/10.1038/323292a0.
Pełny tekst źródłaWilliams, Bryan R. G. "Design of anti-AIDS drugs". Virus Research 19, nr 1 (marzec 1991): 130. http://dx.doi.org/10.1016/0168-1702(91)90102-2.
Pełny tekst źródłaYOKOYAMA, MASAYUKI. "Molecular design of missile drugs." Kagaku To Seibutsu 26, nr 3 (1988): 199–202. http://dx.doi.org/10.1271/kagakutoseibutsu1962.26.199.
Pełny tekst źródłaFerriz, J. M., i J. Vinsova. "Prodrug Design of Phenolic Drugs". Current Pharmaceutical Design 16, nr 18 (1.06.2010): 2033–52. http://dx.doi.org/10.2174/138161210791293042.
Pełny tekst źródłaIsnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal". Pharmaceutical Journal of Indonesia 6, nr 1 (1.12.2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.
Pełny tekst źródłaCarlson, Robert. "Supercomputers help design drugs super fast". Inpharma Weekly &NA;, nr 1155 (wrzesień 1998): 9–10. http://dx.doi.org/10.2165/00128413-199811550-00019.
Pełny tekst źródłaKorcsmáros, Tamás, Máté S. Szalay, Csaba Böde, István A. Kovács i Péter Csermely. "How to design multi-target drugs". Expert Opinion on Drug Discovery 2, nr 6 (czerwiec 2007): 799–808. http://dx.doi.org/10.1517/17460441.2.6.799.
Pełny tekst źródłaRozprawy doktorskie na temat "Drugs design"
Attardo, Giorgio G. (Giorgio Giovanni). "Drug design and synthesis of novel heteroanthracycline antitumor drugs". Thesis, McGill University, 1990. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=74641.
Pełny tekst źródłaAfter extensive studies, three methodologies were developed for the general synthetic plan. The first method involved photoenolisation of 2,5-dimethoxybenzaldehyde and SO$ sb2$ entrapment of the o-quinodimethane to give 4,7-dimethoxy-1-hydroxy-1,3-dihydrobenzo(2,3-c) thiophene-2,2-dioxide. This compound served as a general intermediate towards the synthesis of several heteroanthracyclinones. It could be reduced to the oxathiin-2-oxide derivative which thermally extruded SO$ sb2$ to yield the o-quinodimethane. Reentrapment of this latter intermediate with various glyoxalates gave key isochroman derivatives. The second method is an improvement over the first. Isochromandiones with a C-1 hydroxyl functionality were prepared from oxidative demethylation of 1-hydroxyisochromans. These were obtained after acid hydrolysis of the coupling products between epoxides and the cuprate of 2,5-dimethoxy-6-methylbenzaldehydedioxane acetal. The third method involved a sequential cycloaddition routine with two o-quinodimethanes.
By combining newly developed techniques with known methods, a general synthetic plan was developed. Consequently, the total synthesis of six tetracyclic structural hybrids of the naphthoquinone(2,3-c) pyranyl class of antibiotics was accomplished; along with the total synthesis of (R) and (S) 1-(4$ sp prime$-O-p-nitrobenzoyl-N-trifluoroacetyldaunosamine)-$ 1,3$-dihydrothioxantho(2,3-c) thiophene-2,2-dioxide, p-nitrobenzyl(5,12-dihydroxy-3,4-dihydrothioxantho(2,3-c) and (3,2-c) pyran-3-yl)formate, and eight novel heteroanthracyclines with the 5,12-dioxo-2,3,5,12-tetrahydroanthraceno(2,3-c) pyranyl backbone. The diastereomeric mixture of (1$ sp prime$S, 1R, 3S) and (1$ sp prime$S, 1S, 3R) methyl(11-hydroxy-1-$(2 sp prime,3 sp prime,6 sp prime $-trideoxy-3-trifluoroacetamido-L-lyxohexopyranose)-$5,12 $-dioxo-3,4,5,12-tetrahydroanthraceno(2,3-c) pyran-3-yl) formate was found to possess equipotent antileukemic activity to doxorubicin with no cross resistance.
Zhang, Huarui. "Design, synthesis and activity evaluation of novel exosome inhibitors". HKBU Institutional Repository, 2020. https://repository.hkbu.edu.hk/etd_oa/849.
Pełny tekst źródłaMcCallum, Emma Clare. "Adaptive phase II clinical trial design using nonlinear dose-response models". Thesis, University of Cambridge, 2015. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.709013.
Pełny tekst źródłaMa, Haiqiu. "The formulation, manufacture and evaluation of capsules containing freeze-dried aqueous extracts of Leonotis Leonorus or Mentha Longifolia". Thesis, University of the Western Cape, 2006. http://etd.uwc.ac.za/index.php?module=etd&action=viewtitle&id=gen8Srv25Nme4_3777_1181559333.
Pełny tekst źródłaLeonotis leonorus and Mentha longifolia are two herbs commonly used in South Africa, mostly in oral liquid dosage forms. Several disadvantages are associated with these traditional dosage forms which can perhaps be remedied by using an appropriate oral solid dosage form, provided the actual plant material in the latter still resemble, as closely as possible, the traditionally used material and provide products of suitable pharmaceutical quality. The objectives of this study were to prepare and evaluate the pharmaceutical suitability of the freeze-dried aqueous extracts of Leonotis Leonorus and Mentha Longifolia as plant raw material for the capsule dosage of these two therapies and to formulate and manufacture capsules of Leonotis Leonorus and Mentha Longifolia aqueous extract that would contain amounts of the plant materials equivalent to that found in their traditional liquid dosage forms, and have immediate release characteristics and suitability stability.
Gustafsson, Jörgen. "Synthesis of cyclohexenedicarbaldehydes and studies of their biologic activity". Lund : Organic Chemistry 2, Lund Institute of Technology, University of Lund, 1994. http://books.google.com/books?id=ULpqAAAAMAAJ.
Pełny tekst źródłaMoorad, Razia. "Computer-aided drug design and the biological evaluation of anti-cancer drugs". Doctoral thesis, University of Cape Town, 2016. http://hdl.handle.net/11427/20715.
Pełny tekst źródłaIACUZZI, VALENTINA. "Design of detection systems for the therapeutic drug monitoring of anticancer drugs". Doctoral thesis, Università degli Studi di Trieste, 2020. http://hdl.handle.net/11368/2967986.
Pełny tekst źródłaDespite the continuous progress in drug therapy, most anticancer drugs appear to be characterized by a high interindividual variability in plasma concentrations that is reflected in the efficacy of the treatment. From this arises the need of a personalized approach, so that the drug concentrations in plasma are adequate in each patient. On this basis, during the PhD project reported hereby, different techniques for therapeutic monitoring (TDM) of anticancer drugs were developed. First, a LC-MS/MS method for the quantification of imatinib (IMA) and its active metabolite, norimatinib (norIMA), was developed, validated and cross-validated in patients affected by gastrointestinal stromal tumour. This method allows to perform the quantification directly on a drop of capillary blood, exploiting the dried blood spot (DBS) technique, reducing sampling time, costs and improving patients’ compliance. Analytes were extracted from DBS samples by adding acidified methanol and the extract is injected into a LC system (configured with a 2D chromatography for online cleaning of the sample), coupled with an API-4000QT. The method showed good linearity (R2> 0.996) in the ranges of 50-7500 ng/mL and 10-1500 ng/mL for IMA and norIMA. Intra-day precision and accuracy were ≤3.1% and between 88.9-112.8%, respectively, while inter-day ones were ≤6.6% and between 95.7-104.3 %, for both analytes. Moreover, were also evaluated: the influence of the haematocrit (Hct), of the spot size and of the sample homogeneity on the analysis; the correlation between the concentration in DBS from venous sampling and from finger-prick (% difference between -12 and 3.8%) and the stability of DBSs (up to 16 months). Then, the method was applied for the quantification of 67 DBSs patients’ samples. Good agreement was obtained between IMA and norIMA concentrations found in DBS and plasma samples applying either the Hct normalization or avoiding it, simply multiplying the DBS concentration with a correction factor. Part of the work of this project was also dedicated for the development of alternative strategies for the quantification of anticancer drugs, to promote the application of TDM. In particular, the synthesis of molecularly imprinted polymers (MIPs) was performed, with the future goal of applying them as receptors in a fluorimetric detection system for IMA. MIPs were synthesized using the non-covalent approach and high dilution radical polymerization. Through this synthesis, the MIPs obtained, synthesized in DMSO with methacrylic acid as functional monomer, shown nanometric size (data acquired by dynamic light scattering). The rebinding tests then showed that 2 MIPs in particular were able to bind IMA with a good specificity (compared to the corresponding non-imprinted polymers) and selectivity. Finally, a LC-MS/MS method was developed and validated for the quantification of ribociclib (RIBO), palbociclib (PALBO) and letrozole (LETRO) in human plasma. RIBO and PALBO are drugs belonging to the CDKIs family, recently approved for breast cancer treatment in combination with LETRO. The method developed is suitable for its application in clinical practice, thanks to simple sample preparation and rapid analysis (6.5 min). The method showed a good linearity (R2 between 0.992-0.983) in the concentration ranges of 0.3-250 ng/mL for PALBO, 10-10000 ng mL for RIBO and 0.5-500 ng/mL for LETRO (covering the therapeutic plasma concentrations). Intra-day precision and accuracy were ≤3.6% and between 94.5-112.3% for all and analytes, respectively, while inter-day ones were ≤ 7.3% and 94.5-112.9%. The method has been successfully applied for patients’ plasma samples quantification. In conclusion, with the development of these strategies there is the hope to implement the application of TDM for anticancer drugs in the clinical practice.
Gupta, Sona. "Rational design and delivery of peptide drugs". Thesis, Bangor University, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.323850.
Pełny tekst źródłaSoldevila, Barreda Joan Josep. "Design of catalytic organometallic anti-cancer drugs". Thesis, University of Warwick, 2014. http://wrap.warwick.ac.uk/63808/.
Pełny tekst źródłaTripathi, Ashutosh. "DEVELOPMENT OF HINT BASED COMPUTATIONAL TOOLS FOR DRUG DESIGN: APPLICATIONS IN THE DESIGN AND DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS". VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1866.
Pełny tekst źródłaKsiążki na temat "Drugs design"
Povl, Krogsgaard-Larsen, Liljefors Tommy i Madsen Ulf, red. A Textbook of drug design and development. Wyd. 2. Australia: Harwood Academic Publishers, 1996.
Znajdź pełny tekst źródłaKlesov, A. A. Glycobiology and drug design. Redaktor American Chemical Society. Division of Carbohydrate Chemistry. Washington DC: American Chemical Society, 2012.
Znajdź pełny tekst źródłaPovl, Krogsgaard-Larsen, Strømgaard Kristian i Madsen Ulf, red. Textbook of drug design and discovery. Wyd. 4. Boca Raton: CRC Press/Taylor & Francis, 2010.
Znajdź pełny tekst źródłaKlesov, A. A. Glycobiology and drug design. Redaktor American Chemical Society. Division of Carbohydrate Chemistry. Washington DC: American Chemical Society, 2012.
Znajdź pełny tekst źródłaWilliams, Robert O., Alan B. Watts i Dave A. Miller. Formulating poorly water soluble drugs. New York, NY: AAPS Press, 2012.
Znajdź pełny tekst źródłaFernández, Ariel. Transformative concepts for drug design: Target wrapping. Berlin: Springer, 2010.
Znajdź pełny tekst źródłaWard, David J., B.Sc., red. Peptide pharmaceuticals: Approaches to the design of novel drugs. Milton Keynes: Open University Press, 1991.
Znajdź pełny tekst źródłaB, Weiner David, i Williams William V, red. Biological approaches to rational drug design. Boca Raton: CRC Press, 1995.
Znajdź pełny tekst źródłaEdgar, Kevin J., Charles M. Buchanan i Thomas Heinze. Polysaccharide materials: Performance by design. Washington DC: American Chemical Society, 2009.
Znajdź pełny tekst źródłaM, Ottenbrite Raphael, i Kim Sung Wan, red. Polymeric drugs & drug delivery systems. Lancaster, Pa: Technomic Pub. Co., 2001.
Znajdź pełny tekst źródłaCzęści książek na temat "Drugs design"
Folkers, Gerd, Elvan Kut i Martin Boyer. "Drug Design: Designer Drugs". W X.media.publishing, 53–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-69002-3_5.
Pełny tekst źródłaKlebe, Gerhard. "How Drugs Act: Concepts for Therapy". W Drug Design, 471–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-17907-5_22.
Pełny tekst źródłaWang, Yuxuan, i Ross D. King. "Extrapolation is Not the Same as Interpolation". W Discovery Science, 277–92. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-45275-8_19.
Pełny tekst źródłaKlebe, Gerhard. "Biologicals: Peptides, Proteins, Nucleotides, and Macrolides as Drugs". W Drug Design, 813–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-17907-5_32.
Pełny tekst źródłaNguyen, Jeffrey-Tri, i Yoshiaki Kiso. "Delivery of Peptide Drugs". W Peptide Chemistry and Drug Design, 271–310. Hoboken, NJ, USA: John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118995303.ch8.
Pełny tekst źródłaColman, P. M. "Drugs Targeting Influenza Virus Neuraminidase". W Structure-Based Drug Design, 87–93. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-015-9028-0_8.
Pełny tekst źródłaWorkman, Paul. "Design of Novel Bioreductive Drugs". W New Approaches in Cancer Pharmacology: Drug Design and Development, 63–74. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77874-2_7.
Pełny tekst źródłaFischman, A. J., R. H. Rubin i H. W. Strauss. "In Vivo Imaging in Drug Discovery and Design". W Pharmacokinetics of Drugs, 481–503. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78680-8_17.
Pełny tekst źródłaAdams, Jerry L., Paul Bamborough, David H. Drewry i Lisa Shewchuk. "Strategies for Discovering Kinase Drugs". W Gene Family Targeted Molecular Design, 119–57. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2008. http://dx.doi.org/10.1002/9780470423936.ch5.
Pełny tekst źródłaJacobs, Terry. "Chapter 4 Architectural Design Issues". W Drugs and the Pharmaceutical Sciences, 89–124. 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742: CRC Press, 2016. http://dx.doi.org/10.1201/9781315372242-5.
Pełny tekst źródłaStreszczenia konferencji na temat "Drugs design"
Rautiola, Davin, i Ronald A. Siegel. "Nasal Spray Device for Administration of Two-Part Drug Formulations". W 2019 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/dmd2019-3216.
Pełny tekst źródłaLee, Jae-Hwan, i Ramana M. Pidaparti. "An Implantable Device Design Concept for Ocular Drug Delivery". W ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80176.
Pełny tekst źródłaGroeneveld, Patrick, Rob A. Rutenbar, Jed Pitera, Erik Carlson i Jinsong Chen. "Oil fields, hedge funds, and drugs". W the 46th Annual Design Automation Conference. New York, New York, USA: ACM Press, 2009. http://dx.doi.org/10.1145/1629911.1630021.
Pełny tekst źródłaMendes, Pedro J., Joa˜o M. M. Sousa i Joa˜o F. Pinto. "A Virtual Apparatus for Design and Testing of New Drug Formulations and Devices for Inhalation Therapy". W ASME 2007 2nd Frontiers in Biomedical Devices Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/biomed2007-38027.
Pełny tekst źródłaDolla, William Jacob S., Brian A. Fricke i Bryan R. Becker. "Auxetic Drug-Eluting Stent Design". W ASME 2006 Frontiers in Biomedical Devices Conference. ASMEDC, 2006. http://dx.doi.org/10.1115/nanobio2006-18035.
Pełny tekst źródłaChebrolu, Anika. "DeepLig: A De-Novo Computational Drug Design Approach to Generate Multi-Targeted Drugs". W 2023 Fifth International Conference on Transdisciplinary AI (TransAI). IEEE, 2023. http://dx.doi.org/10.1109/transai60598.2023.00013.
Pełny tekst źródłaLiu, Miao, i Wenjun Wang. "Analysis of antibiotic purchasing service design based on SAPAD-AHP method". W 13th International Conference on Applied Human Factors and Ergonomics (AHFE 2022). AHFE International, 2022. http://dx.doi.org/10.54941/ahfe1002124.
Pełny tekst źródłaFeng, Yu, Xiaole Chen i Mingshi Yang. "An In Silico Investigation of a Lobe-Specific Targeted Pulmonary Drug Delivery Method". W 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6928.
Pełny tekst źródłaSutopo, Hadi, i Ridha Sefina Samosir. "Mobile Multimedia Stop Drugs Tutorial Development". W Proceedings of the 3rd International Conference on Creative Media, Design and Technology (REKA 2018). Paris, France: Atlantis Press, 2018. http://dx.doi.org/10.2991/reka-18.2018.78.
Pełny tekst źródłaZarandi, Marjan Molavi, Rosaire Mongrain i Olivier F. Bertrand. "Modeling Drug Eluting Stents for Coronary Artery Bifurcation Considering Non-Newtonian Effects". W ASME 2010 3rd Joint US-European Fluids Engineering Summer Meeting collocated with 8th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2010. http://dx.doi.org/10.1115/fedsm-icnmm2010-31190.
Pełny tekst źródłaRaporty organizacyjne na temat "Drugs design"
Taufer, Michela, Sandeep Patel i Narayan Ganesan. Computer-Aided Design of Drugs on Emerging Hybrid High Performance Computers. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2013. http://dx.doi.org/10.21236/ada607433.
Pełny tekst źródłaZhang, Cheng, i Yue Yang. Impact of adaptive design on reducing the duration of clinical trials in rare cancers: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2022. http://dx.doi.org/10.37766/inplasy2022.2.0081.
Pełny tekst źródłaMatthews, Lisa, Guanming Wu, Robin Haw, Timothy Brunson, Nasim Sanati, Solomon Shorser, Deidre Beavers, Patrick Conley, Lincoln Stein i Peter D'Eustachio. Illuminating Dark Proteins using Reactome Pathways. Reactome, październik 2022. http://dx.doi.org/10.3180/poster/20221027matthews.
Pełny tekst źródłaBoaden, Dr Bill. Syringe labelling in anaesthesia and critical care areas: review 2022. Association of Anaesthetists of Great Britain and Ireland, wrzesień 2022. http://dx.doi.org/10.21466/g.sliaacc.2022.
Pełny tekst źródłaBiazus-Dalcin, Camila, Louise Marryat, Sarah Gray, Andrea Mohan, Senga Robertson-Albertyn, Sreekanth Thekkumkara, Hazel Booth i in. My data: an animated film, co-produced with people who use drugs. University of Dundee, 2023. http://dx.doi.org/10.20933/100001299.
Pełny tekst źródłaDong, Chengda, Hongshuo Shi, Zhaojun Yan i Jianmin Liu. Quality of Evidence Supporting the Role of Nonsteroidal Anti-inflammatory Drugs for the Treatment of Anxious Depression: A protocol for Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, sierpień 2022. http://dx.doi.org/10.37766/inplasy2022.8.0029.
Pełny tekst źródłaAnderson, Burt, Richard Heller, Ed Turos i Mark Mclaughlin. Drug Discovery, Design and Delivery. Fort Belvoir, VA: Defense Technical Information Center, czerwiec 2012. http://dx.doi.org/10.21236/ada563482.
Pełny tekst źródłaMarks, James. Structural Basis of EGFR Dimerization for Drug Design. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2000. http://dx.doi.org/10.21236/ada396569.
Pełny tekst źródłaMenlove, H. O., D. B. Beddingfield i M. M. Pickrell. Passive neutron design study for 200-L waste drums. Office of Scientific and Technical Information (OSTI), wrzesień 1997. http://dx.doi.org/10.2172/534520.
Pełny tekst źródłaRodgers, L. A. ,. ICP Kaiser Hanford. Shielding design evaluations of concrete-lined drums for RH-Truwaste. Office of Scientific and Technical Information (OSTI), czerwiec 1996. http://dx.doi.org/10.2172/657964.
Pełny tekst źródła